JP2021534208A5 - - Google Patents
Info
- Publication number
- JP2021534208A5 JP2021534208A5 JP2021510013A JP2021510013A JP2021534208A5 JP 2021534208 A5 JP2021534208 A5 JP 2021534208A5 JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021534208 A5 JP2021534208 A5 JP 2021534208A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- subject
- ezetimibe
- composition according
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024032974A JP2024081650A (ja) | 2018-08-24 | 2024-03-05 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722766P | 2018-08-24 | 2018-08-24 | |
| US62/722,766 | 2018-08-24 | ||
| US201862751404P | 2018-10-26 | 2018-10-26 | |
| US62/751,404 | 2018-10-26 | ||
| PCT/US2019/048184 WO2020041799A1 (en) | 2018-08-24 | 2019-08-26 | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024032974A Division JP2024081650A (ja) | 2018-08-24 | 2024-03-05 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534208A JP2021534208A (ja) | 2021-12-09 |
| JP2021534208A5 true JP2021534208A5 (https=) | 2022-11-09 |
Family
ID=69591419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510013A Pending JP2021534208A (ja) | 2018-08-24 | 2019-08-26 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
| JP2024032974A Pending JP2024081650A (ja) | 2018-08-24 | 2024-03-05 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024032974A Pending JP2024081650A (ja) | 2018-08-24 | 2024-03-05 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210322376A1 (https=) |
| EP (1) | EP3841105A4 (https=) |
| JP (2) | JP2021534208A (https=) |
| KR (1) | KR20210079275A (https=) |
| CN (1) | CN113166195A (https=) |
| AU (1) | AU2019325705A1 (https=) |
| BR (1) | BR112021003265A2 (https=) |
| CA (1) | CA3110346A1 (https=) |
| CL (1) | CL2021000444A1 (https=) |
| CO (1) | CO2021003726A2 (https=) |
| IL (1) | IL281016A (https=) |
| MX (1) | MX2021002090A (https=) |
| PH (1) | PH12021550656A1 (https=) |
| SG (1) | SG11202101717WA (https=) |
| WO (1) | WO2020041799A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3267989A4 (en) | 2015-03-13 | 2018-11-07 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| US20210322375A1 (en) * | 2018-08-27 | 2021-10-21 | Esperion Therapeutics, Inc. | Combination drug formulations for treating patients with cardiovascular disease and associated conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000684A1 (es) * | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CN103239449A (zh) * | 2012-12-26 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法 |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2018148417A1 (en) * | 2017-02-08 | 2018-08-16 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease |
-
2019
- 2019-08-26 MX MX2021002090A patent/MX2021002090A/es unknown
- 2019-08-26 EP EP19852458.9A patent/EP3841105A4/en active Pending
- 2019-08-26 JP JP2021510013A patent/JP2021534208A/ja active Pending
- 2019-08-26 US US17/271,045 patent/US20210322376A1/en active Pending
- 2019-08-26 SG SG11202101717WA patent/SG11202101717WA/en unknown
- 2019-08-26 KR KR1020217008742A patent/KR20210079275A/ko not_active Ceased
- 2019-08-26 CA CA3110346A patent/CA3110346A1/en active Pending
- 2019-08-26 PH PH1/2021/550656A patent/PH12021550656A1/en unknown
- 2019-08-26 WO PCT/US2019/048184 patent/WO2020041799A1/en not_active Ceased
- 2019-08-26 BR BR112021003265-7A patent/BR112021003265A2/pt unknown
- 2019-08-26 AU AU2019325705A patent/AU2019325705A1/en not_active Abandoned
- 2019-08-26 CN CN201980067823.7A patent/CN113166195A/zh active Pending
-
2021
- 2021-02-22 CL CL2021000444A patent/CL2021000444A1/es unknown
- 2021-02-22 IL IL281016A patent/IL281016A/en unknown
- 2021-03-24 CO CONC2021/0003726A patent/CO2021003726A2/es unknown
-
2024
- 2024-03-05 JP JP2024032974A patent/JP2024081650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7629049B2 (ja) | 貧血治療のための組成物及び方法 | |
| CA3043284C (en) | Treatment for fibrosis | |
| KR102338085B1 (ko) | 담즙울체성 질환의 치료 방법 | |
| JP2024081650A5 (https=) | ||
| JP2023501457A5 (https=) | ||
| US20190175619A1 (en) | Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| JP2022542830A (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| JP2021534208A5 (https=) | ||
| Althubiti | Tyrosine kinase targeting: a potential therapeutic strategy for diabetes | |
| WO2011150067A1 (en) | Treatment of blood lipid abnormalities and other conditions | |
| WO2025007946A1 (zh) | 治疗前列腺癌的方法 | |
| Friedman et al. | Effect of glucagon on blood-cholesterol levels in rats | |
| KR20210079275A (ko) | 고콜레스테롤 관련 병으로 치료 받고 있는 환자에서의 당뇨병의 위험 감소 방법 | |
| RU2021107420A (ru) | Способы снижения риска сахарного диабета у больных, подлежащих лечению от заболеваний, связанных с высоким содержанием холестерина | |
| US20250332176A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| US12616698B2 (en) | Methods for reducing liver fat and for treating fatty liver disorders | |
| AU2019376907B2 (en) | Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| US20240100052A1 (en) | METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS | |
| US20220362263A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| Wilkinson et al. | * Real-World Experience with Inclisiran at a Large Academic Lipid Clinic | |
| CN117100748A (zh) | 罗沙司他在制备治疗慢性肾脏病高脂血症药物中的应用 | |
| Leskovar et al. | Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach | |
| WO2025036347A1 (zh) | Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法 | |
| Villeneuve et al. | Treatment of Chronic Hepatitis B with Interferon: Long Term Follow‐Up | |
| TW202517250A (zh) | Ｌｐ（ａ）干擾劑化合物之治療用途及劑量 |